Shenzhen Bioeasy Biotechnology Co. Ltd. Net Assets
Shenzhen Bioeasy Biotechnology Co. Ltd. net assets. Based on the latest financial reports, Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has net assets worth CN¥899.42 Million CNY (≈ $131.61 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.49 Billion ≈ $217.74 Million USD) and total liabilities (CN¥588.54 Million ≈ $86.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Shenzhen Bioeasy Biotechnology Co. Ltd. equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥899.42 Million |
| % of Total Assets | 60.45% |
| Annual Growth Rate | 36.49% |
| 5-Year Change | -4.11% |
| 10-Year Change | N/A |
| Growth Volatility | 53.6 |
Net Assets of Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
Net assets of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025. This chart illustrates how Shenzhen Bioeasy Biotechnology Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. See Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
The table below shows the annual net assets of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025. For live market cap and overall valuation, see market cap of Shenzhen Bioeasy Biotechnology Co. Ltd..
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥907.68 Million ≈ $132.82 Million |
+4.30% |
| 2024-12-31 | CN¥870.24 Million ≈ $127.34 Million |
+2.53% |
| 2023-12-31 | CN¥848.73 Million ≈ $124.20 Million |
-12.02% |
| 2022-12-31 | CN¥964.70 Million ≈ $141.17 Million |
+1.91% |
| 2021-12-31 | CN¥946.58 Million ≈ $138.51 Million |
+72.42% |
| 2020-12-31 | CN¥548.98 Million ≈ $80.33 Million |
+3.91% |
| 2019-12-31 | CN¥528.32 Million ≈ $77.31 Million |
+137.32% |
| 2018-12-31 | CN¥222.62 Million ≈ $32.58 Million |
+94.25% |
| 2017-12-31 | CN¥114.60 Million ≈ $16.77 Million |
+107.47% |
| 2016-12-31 | CN¥55.24 Million ≈ $8.08 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shenzhen Bioeasy Biotechnology Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 296.7% over the analyzed period, indicating profitable operations and earnings retention.
Shenzhen Bioeasy Biotechnology Co. Ltd. Net Assets Breakdown (December 2025)
Shenzhen Bioeasy Biotechnology Co. Ltd. net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥160.24 Million | 17.72% |
| Other Components | CN¥743.84 Million | 82.28% |
| Total Equity | CN¥904.08 Million | 100.00% |
Shenzhen Bioeasy Biotechnology Co. Ltd. Competitors by Market Cap
The table below lists competitors of Shenzhen Bioeasy Biotechnology Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangsu Nanfang Medical
SHG:603880
|
$342.17 Million |
|
Frontera Energy Corp
TO:FEC
|
$342.24 Million |
|
Dhani Services Limited
NSE:DHANI
|
$342.32 Million |
|
Chongqing Sansheng Building Materials Co Ltd
SHE:002742
|
$342.36 Million |
|
FS Bancorp Inc
NASDAQ:FSBW
|
$342.00 Million |
|
Morguard Real Estate Investment Trust
TO:MRT-UN
|
$341.61 Million |
|
ALPHA
KLSE:0303
|
$341.50 Million |
|
Hamilton Beach Brands Holding Co Class A
NYSE:HBB
|
$341.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shenzhen Bioeasy Biotechnology Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 869,005,338 to 904,080,226, a change of 35,074,888 (4.0%).
- Net income of 13,743,334 contributed positively to equity growth.
- Dividend payments of 13,857,304 reduced retained earnings.
- Other factors increased equity by 35,188,859.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥13.74 Million | +1.52% |
| Dividends Paid | CN¥13.86 Million | -1.53% |
| Other Changes | CN¥35.19 Million | +3.89% |
| Total Change | CN¥- | 4.04% |
Book Value vs Market Value Analysis
This analysis compares Shenzhen Bioeasy Biotechnology Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.05x to 2.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥5.52 | CN¥5.77 | x |
| 2017-12-31 | CN¥1.58 | CN¥5.77 | x |
| 2018-12-31 | CN¥4.28 | CN¥5.77 | x |
| 2019-12-31 | CN¥1.49 | CN¥5.77 | x |
| 2020-12-31 | CN¥1.51 | CN¥5.77 | x |
| 2021-12-31 | CN¥2.40 | CN¥5.77 | x |
| 2022-12-31 | CN¥2.44 | CN¥5.77 | x |
| 2023-12-31 | CN¥2.11 | CN¥5.77 | x |
| 2024-12-31 | CN¥2.03 | CN¥5.77 | x |
| 2025-12-31 | CN¥2.23 | CN¥5.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shenzhen Bioeasy Biotechnology Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.52%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.22%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.69x
- Recent ROE (1.52%) is below the historical average (15.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 42.42% | 26.93% | 0.71x | 2.23x | CN¥17.91 Million |
| 2017 | 34.27% | 28.50% | 0.79x | 1.52x | CN¥27.83 Million |
| 2018 | 33.20% | 36.08% | 0.69x | 1.33x | CN¥51.67 Million |
| 2019 | 17.47% | 38.59% | 0.39x | 1.17x | CN¥39.47 Million |
| 2020 | 11.92% | 25.32% | 0.40x | 1.19x | CN¥10.54 Million |
| 2021 | 25.03% | 39.58% | 0.52x | 1.22x | CN¥142.03 Million |
| 2022 | 8.60% | 12.08% | 0.54x | 1.33x | CN¥-13.52 Million |
| 2023 | -21.78% | -72.77% | 0.19x | 1.60x | CN¥-269.81 Million |
| 2024 | 1.97% | 7.63% | 0.15x | 1.68x | CN¥-69.78 Million |
| 2025 | 1.52% | 5.22% | 0.17x | 1.69x | CN¥-76.66 Million |
Industry Comparison
This section compares Shenzhen Bioeasy Biotechnology Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,971,753,361
- Average return on equity (ROE) among peers: 9.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) | CN¥899.42 Million | 42.42% | 0.65x | $342.02 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $15.70 Million | 0.00% | 0.12x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $137.64 Million | 1.69% | 8.09x | $1.37 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $384.41 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $156.83 Million | 24.69% | 0.38x | $473.06 Million |
| Chengzhi Shareholding Co Ltd (000990) | $663.54 Million | 6.09% | 0.18x | $1.28 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.36 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $256.72 Million | 9.82% | 0.22x | $1.10 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $4.78 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $469.29 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.45 Billion | 14.73% | 0.06x | $1.63 Billion |
About Shenzhen Bioeasy Biotechnology Co. Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd., together with its subsidiaries, provides rapid food testing reagents and instruments in China and internationally. The company offers test kits, including veterinary, melamine, mycotoxin, pesticide, adulteration, ATP, vitamin, and others; equipment, such as incubator, reader, suitcase lab, automatic pressers, and others; and materials comprising pretreatm… Read more